FDA Clears Path for Generic Sleep-Aid Tablets
Published Date: 7/9/2026
Notice
Summary
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generics May Be Approved for TOVALT ODT
The FDA determined that TOVALT ODT (zolpidem tartrate) orally disintegrating tablets, 5 mg and 10 mg, were not withdrawn for reasons of safety or effectiveness. Because of that decision, the FDA can approve abbreviated new drug applications (ANDAs) that refer to these 5 mg and 10 mg products if the ANDA meets all other legal and regulatory requirements.
Orange Book Listing and ANDA Labeling Guidance
FDA will continue to list TOVALT ODT (zolpidem tartrate) 5 mg and 10 mg in the "Discontinued Drug Product List" section of the Orange Book, which denotes discontinuation for reasons other than safety or effectiveness. ANDAs that refer to these listed products may be approved if they meet legal requirements, and FDA said it will advise ANDA applicants to submit revised labeling if the Agency determines labeling should be updated to meet current standards.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2026-13819 — Polypropylene Corrugated Boxes From Vietnam; Determination
The U.S. International Trade Commission found that American companies making polypropylene corrugated boxes are hurt by cheaper imports from Vietnam sold below fair prices. This means extra duties will be applied to these imports to protect U.S. businesses. The decision follows a 2025 investigation and affects importers starting mid-2026, helping local makers stay competitive.
Next: 2026-13822 — Datum One Series Trust and Brandes Investment Partners, L.P.
Datum One Series Trust and Brandes Investment Partners want to create a new kind of investment fund that offers both exchange-traded shares (like ETFs) and regular mutual fund shares all in one. This change could make investing easier and more flexible for people using these funds. If no one asks for a hearing by July 31, 2026, the SEC will likely approve this new setup soon.